Abiopharma

Completion of Share Buy-back Program

New Form 424B3 - Autolus Therapeutics plc Filed: 2025-06-30 AccNo: 0001730463-25-000050 Size: 131 KB

New Form 8-K - Unicycive Therapeutics, Inc. Filed: 2025-06-30 AccNo: 0001213900-25-059303 Size: 231 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Senti Bio Participates in Nasdaq Amplify Spotlight Series

New Form 424B5 - Inmune Bio, Inc. Filed: 2025-06-30 AccNo: 0001213900-25-059298 Size: 242 KB

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Zynex Announces Steven Dyson as New CEO

New Form 6-K - Regencell Bioscience Holdings Ltd Filed: 2025-06-30 AccNo: 0001213900-25-059294 Size: 15 KB

New Form 4 - Immuneering Corp Filed: 2025-06-30 AccNo: 0001790340-25-000089 Size: 4 KB

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

New Form 15-12G - Kronos Bio, Inc. Filed: 2025-06-30 AccNo: 0001140361-25-024105 Size: 15 KB